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TA B L E 1 Patients demographic and clinical characteristics
Patient
Improved
Improvement in the symptoms, activity, impact and total score was seen in 8 (44%), 5 (28%), 7 (39%) and 6 (33%) of the patients, respectively. Stability in the symptoms, activity, impact and total score was seen in 6 (33%), 7 (39%), 2 (11%) and 3 (17%) of the patients, respectively. Deterioration in the symptoms, activity, impact and total score was seen in 4 (22%), 6 (33%), 9 (47%) and 9 (47%) of the patients, respectively.
BAE, bronchial artery embolisation; COPD, chronic obstructive pulmonary disease; F, female; M, male; MRC, medical research council; OPAT, outpatient parenteral antimicrobial therapy; SCLC, small cell lung cancer; X 0 , at start of OPAT; X infections in an outpatient setting or in their own home. 7, 8 The OPAT service at the Wythenshawe Hospital site of Manchester University NHS Foundation Trust was established in 2015 and is run by a multidisciplinary team based in the Infectious Diseases Department, which also incorporates the National Aspergillosis Centre (NAC).
The OPAT service has facilitated the discharge from hospital of patients requiring IV micafungin for treatment of their CPA. Here, we reviewed OPAT episodes during which CPA patients received micafungin.
| MATERIAL S AND ME THODS
All CPA patients who completed a course of micafungin through OPAT between April 2016 and March 2018 were included in the study. The diagnosis of CPA was made using a combination of characteristics: a consistent appearance on thoracic imaging, direct evidence of Aspergillus infection or an immunological response to
Aspergillus spp. and exclusion of some alternative diagnoses. 7 All patients initially received micafungin as an inpatient before being discharged via OPAT. All patients received daily doses of IV micafungin (7 days a week). Some OPAT administered doses were initially given via peripheral cannulae but most doses were given via peripherally inserted central catheter (PICC) lines.
All data were collected retrospectively from case notes and the NAC database of CPA patients. Demographic, clinical and laboratory data were recorded. Where available, St George's Respiratory Questionnaire (SGRQ) Quality of Life (QoL) scores at the start of micafungin course and 3 months later were extracted to assess response to therapy. Improvements in QoL were defined as an improvement of ≥4 points in at least one modality (symptom, impact, activity, total) in the St George's QoL score. 8 A stable QoL score was defined as a change in score of <4 points in either direction whilst deterioration was defined as an increase of ≥4 points. 9 The symptoms component assesses for frequency and severity of disease; activity component assesses for activities of daily living that cause or are limited by breathlessness; impact component is the broadest component of the questionnaire that covers a vast range of disturbances of psychosocial function. The total score summarises the impact of the disease on overall health status and is calculated using the formula 10 :
Scores for all components range from 0 to 100, with higher scores indicating more limitations. Best performances are achieved with a 3-or 12-month recall reported by the patient. 9 The Medical Research Council (MRC) dyspnoea score, patients' assessment of health status (self-assessments), and weight data
were also recorded at the start of OPAT and 3 months later.
Categorical data were reported as total numbers and percent- 
| RE SULTS
There were 20 OPAT episodes involving 18 patients (11 males, seven females), with two patients receiving two courses of micafungin during the study period. The indications for micafungin therapy were intolerance to azoles (10; 48%), panazole resistance (8; 38%) and rapid disease progression despite azole treatment (3; 14%). The me- Quality of Life data were available for 18 patients; improvement or stability in the symptoms and activity domains was observed in over two-thirds of the patients after 3 months of micafungin therapy. However, half of the patients reported deterioration in the impact domain and total scores (Table 1) . Improvement in the symptoms, activity, impact and total score was seen in 8 (44%), 5 (28%), 7 (39%) and 6 (33%) of the patients, respectively (Table 1 ). There was no statistical difference between QoL change and duration of treatment (P = 0.8). By self-assessment, patients who categorised themselves as "poor" were comparable at the start of OPAT and at 3 months (43% vs 50%, McNemar's P = 0.7).
There was no significant difference observed in either weight (61.0 vs 62.8 kg; P = 0.5) or MRC dyspnoea scores (4/5 vs 4/5, P = 0.8) at the start of treatment and 3 months after treatment (Table 1) .
No line-related complications were recorded during micafungin therapy. Of the 20 OPAT episodes, adverse events, which could be attributed to micafungin, were recorded in 3(14%) of these. All the adverse events were classed as type A adverse drug reactions.
None of the OPAT episodes were discontinued due to adverse drug 1 week of micafungin therapy. A total of two of (10%) of the OPAT episodes were characterised by readmission of the patient into hospital. On both occasions, the indication of the admission was recurrent hemoptysis; one required two bronchial artery embolisation procedures and was subsequently switched to liposomal amphotericin B.
| D ISCUSS I ON
About 10% of CPA patients at the NAC have received at least one course of either intravenous micafungin or liposomal amphotericin B during the course of their disease treatment. 11 Our experience with the use of short courses of liposomal amphotericin in CPA patients has previously been reported. 12 Here, we have described our experience of administering micafungin to CPA patients via OPAT.
At 3 months post-commencement of micafungin, there was no significant change in weight or dyspnoea, and only a third of the patients had a clinically significant improvement in their quality of life.
The clinical response seen was much less than those seen in reports of previous randomized clinical trials (RCTs) of micafungin with or without amphotericin B or triazoles. 13, 14 This could be because the median duration of micafungin therapy was shorter in our study, and our patients received micafungin as monotherapy as opposed to combination with amphotericin B and triazoles. Although Kohno et al 14 reported a higher rate of adverse reactions (15.8%) among a cohort of Japanese patients, these were all mild with the most common being abnormal liver function. In a retrospective study, Izumikawa et al 6 reported a higher effectiveness (75%) of micafungin monotherapy than we did and no notable side effects were documented.
Since its development in the 1970s, the use of OPAT has become widespread in both primary and secondary care across many countries. The aims of OPAT include improving patient experience, and provision of care closer to home thereby improving patient experience while decreasing cost and length of hospital stay. Following assessment to determine medical and social suitability by a doctor or specialist nurse, plans are put in place to ensure the efficient daily delivery of the drug with provision made for review by a health professional at regular intervals.
Micafungin is an echinocandin that acts through inhibition of β- Micafungin has been used in a mixed population of patients with subacute invasive aspergillosis (chronic necrotising) and CPA, with reasonable success rates (efficacy) and acceptable safety. 4, 10 Reported doses used in previous studies ranged from 12.5 to 300 mg OD with adverse events rates between 0% and 16%. 4, 5, 14 This is comparable with our data; we observed just over 10% of the patients developing adverse events. Common reported adverse events associated with micafungin include abdominal pain; anaemia; diarrhoea; fever; headache; hypocalcaemia; hypokalaemia; hypomagnesaemia; leukopenia;
phlebitis; rash and vomiting.
| Limitations
We focused on the duration of micafungin administration of micafungin via OPAT and did not assess for inpatient use of micafungin among this cohort. It is possible that some patients received several doses of micafungin as inpatients prior to discharge on OPAT. Also, we were unable to assess for radiological response at the end of the course of micafungin therapy; clear treatment outcome definitions for micafungin use in the setting of CPA are yet to be clearly established. Our study design was retrospective and our findings were limited to what information was available from records. However, to the best of our knowledge, this is the first study to assess the safety and efficacy of IV micafungin administered via OPAT services for the treatment of CPA.
| CON CLUS IONS
Despite the above limitations, the present study has shown that for the majority of CPA patients who received micafungin via OPAT, the course of therapy was well tolerated and no adverse events were recorded. Although this is a small sample size, our experience of using micafungin resulted in lower rates of clinical response than previously reported. However, we were able to demonstrate that micafungin can be safely administered via OPAT and therefore may have a role to play in facilitating the discharge of patients requiring micafungin for other fungal infections, including Candida infections.
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